ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company dedicated to developing therapies that enhance the immune system's ability to combat cancer and extend patients' lives. Headquartered in South San Francisco, California, the company's mission centers on leveraging its expertise in protein engineering and oncology to create novel product candidates.

The company's primary product candidate is evorpacept, a CD47 blocking therapeutic biologic. This next-generation checkpoint inhibitor is designed to have a high affinity for CD47 while minimizing the hematologic toxicities associated with earlier CD47 blocking approaches. ALX Oncology also has ALX2004 in its clinical pipeline, an epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC). These therapies are being developed for various solid tumors and hematologic malignancies.

Recent developments include the company's report of fourth-quarter and full-year 2025 financial results in February 2026, alongside updates on the clinical progress of evorpacept and ALX2004. In January 2026, ALX Oncology announced topline biomarker data from an exploratory analysis for the evorpacept/zanidatamab combination in HER2-positive breast cancer, suggesting CD47 as a predictive biomarker. The company also initiated enrollment for its Phase 2 ASPEN-09-Breast trial for evorpacept in HER2-positive breast cancer and advanced ALX2004 to the third dose cohort in its Phase 1 trial in January 2026. Leadership updates include the appointment of Jeff Knight as Chief Development and Operating Officer in April 2026.